Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor

Siiri Altraja1,2, Martin Kadai3, Erki Rekker4 and Alan Altraja*4

Address: 1Institute of General & Molecular Pathology, University of Tartu, Tartu, Estonia, 2Estonian Biocentre, Tartu, Estonia, 3Institute of Molecular & Cell Biology, University of Tartu, Tartu, Estonia and 4Department of Pulmonary Medicine, University of Tartu, Tartu, Estonia

Email: Siiri Altraja - siiri.altraja@ut.ee; Martin Kadai - kada@ut.ee; Erki Rekker - erx@ut.ee; Alan Altraja* - alan@kliinikum.ee

* Corresponding author

Abstract

**Background:** Cysteinyl leukotrienes (CysLTs) are key mediators of asthma, but their role in the genesis of airway remodeling is insufficiently understood. Recent evidence suggests that increased expression of tenascin (Tn) and laminin (Ln) β2 chain is indicative of the remodeling activity in asthma, but represents also an example of deposition of extracellular matrix, which affects the airway wall compliance. We tested the hypothesis that CysLTs affect production of Tn and Ln β2 chain by human bronchial epithelial cells and elucidated, which of the CysLT receptors, CysLT1 or CysLT2, mediate this effect.

**Methods:** Cultured BEAS-2B human bronchial epithelial cells were stimulated with leukotriene D4 (LTD4) and E4 (LTE4) and evaluated by immunocytochemistry, Western blotting, flow cytometry, and RT-PCR. CysLT receptors were differentially blocked with use of montelukast or BAY u9773.

**Results:** LTD4 and LTE4 significantly augmented the expression of Tn, whereas LTD4, distinctly from LTE4, was able to increase also the Ln β2 chain. Although the expression of CysLT2 prevailed over that of CysLT1, the up-regulation of Tn and Ln β2 chain by CysLTs was completely blocked by the CysLT1-selective antagonist montelukast with no difference between montelukast and the dual antagonist BAY u9773 for the inhibitory capacity.

**Conclusion:** These findings suggest that the CysLT-induced up-regulation of Tn and Ln β2 chain, an important epithelium-linked aspect of airway remodeling, is mediated predominantly by the CysLT1 receptor. The results provide a novel aspect to support the use of CysLT1 receptor antagonists in the anti-remodeling treatment of asthma.

**Background**

Airway remodeling is a fundamental abnormality in the pathobiology of inflammatory airway diseases like bronchial asthma and chronic obstructive pulmonary disease (COPD) [1,2]. This remodeling is irreversible in its many aspects including airway fibrosis and deposition of new extracellular matrix (ECM) components into the airway wall [2]. These events lead to a thickened airway wall with markedly reduced airway caliber resulting in progressive development of fixed airflow limitation [2-4]. In asthmatics, increased deposition of collagen types I and III, but also tenascin (Tn) and laminin (Ln) chains α2 and β2...
beneath the airway epithelium have been described [5-7], whereas the subepithelial Tn deposition is severity-dependent and can be reduced by anti-inflammatory treatment [7]. In bronchial epithelial cells in vitro, Tn can be up-regulated by cytokines like transforming growth factor-β (TGF-β) [8] and tumor necrosis factor-α (TNF-α) [9], which are also operative in asthma. Judged by rapid turnover of Tn in the bronchial mucosa [10], the up-regulation of Tn in asthma may refer to its role in inflammation and immediate repair. However, in addition to serving as a marker of ongoing inflammation, the deposition of Tn can contribute to increased airway narrowing and decreased airway wall compliance, as does the deposition of other ECM components.

Experimental data suggest that cysteinyl leukotrienes (CysLTs), known mainly as effector mediators in asthma, induce a broad spectrum of pathophysiological responses [11]. CysLTs contribute to airway remodeling not only through their diverse roles in inflammation, but also by their direct effects on lung mesenchymal cells [12-15]. CysLTs mediate their diverse effects through at least two G-protein coupled receptors, CysLT1 and CysLT2. Both receptors have been described in a variety of human cells, including inflammatory cells like monocytes/macrophages, mast cells and eosinophils [16,17], expressed predominantly on the outer plasma membrane. Recently, also an agonist-regulated localization of the CysLT1 in the outer nuclear membrane was demonstrated in certain cells [18,19].

Specific antagonists for CysLT1, such as montelukast and zafirlukast, have been developed as active controller medicines for asthma [20], whereas a dual antagonist, BAY u9773, is available for experimental use [21]. Apart from reduction of airway subepithelial fibrosis by blockade of the CysLT1 receptor with montelukast in a murine model [22] and attenuation of airway myofibroblasts by montelukast in human asthmatics following allergen challenge, the knowledge about the effects of antileukotrienes on remodeling of the airway ECM in humans is overall very limited [11,15]. Since a failure in the injury-repair cycle of the inflamed bronchial epithelium seems to play a major role in the remodeling via development of abnormally activated epithelial-mesenchymal interactions [3,11,23,24], a study was undertaken on human bronchial epithelial cells to investigate whether CysLTs have a direct effect on the synthesis of Tn and Ln β2 chain, proteins thought both to reflect the activity of the ongoing inflammatory remodeling and to affect airway compliance in asthma. In this study, we also checked the differential expression of both CysLT receptors on these cells and showed that although CysLT1 is significantly more abundant in human bronchial epithelium, the enhanced expression of the ECM proteins is mediated singly by CysLT1.

Materials and methods

Cell culture
Normal human bronchial epithelial cells (line BEAS-2B) were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured at 37°C in a humidified atmosphere of 5% CO2 using serum-free epithelial growth medium (BEGM; Cambrex, Walkersville, MD, USA) supplemented with Bullet Kit (Cambrex) to contain 0.5 ng/ml human recombinant epidermal growth factor, 50 μg/ml bovine pituitary extract, 0.5 μg/ml hydrocortisone, 5 μg/ml insulin, 10 μg/ml transferrin, 0.5 μg/ml epinephrine, 0.1 ng/ml retinoic acid, 6.5 ng/ml triiodothyronine, 50 μg/ml gentamicin and 50 ng/ml amphotericin B. After reaching 50% subconfluency, the cells were challenged with 0 to 100 nM concentrations of either LTD4, the most potent or LTE4, the weakest though the most stable of the CysLTs (both from Cayman Chemical, Ann Arbor, MI, USA) during 24, 48, and 72 hours. TGF-β1 (1 ng/ml) (Chemicon, Hampshire, UK), known to stimulate Tn expression in BEAS-2B cells [8], served as a positive control. Montelukast sodium (1 μM, Merck-Frosst, Pointe Claire, Quebec, Canada) or BAY u9773 (1 μM, Cayman Chemical) was added to the cell culture for 30 min before challenging with LTD4 or LTE4 to block the CysLT effect mediated via CysLT1, or both CysLT receptors, respectively. In settings, where LTD4-stimulation was involved, parallel experiments were performed with the presence of 5 mM L-cysteine (Sigma, St. Louis, MO, USA) in the media to inhibit catabolism of LTD4 into LTE4.

Antibodies
Mouse monoclonal antibody (clone 100EB2), which recognizes the fourth and fifth fibronectin-like repeats in TnC [25] and reacts with two different Tn polypeptides, was kindly donated by Prof. I. Virtanen (University of Helsinki, Finland). Mouse monoclonal antibody (clone C4) against β2 chain of human Ln was obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA, USA). Rabbit polyclonal antibodies against human CysLT1 and CysLT2 were from Cayman Chemical. Horseradish peroxidase (HRP)-conjugated rabbit anti-mouse and swine anti-rabbit antibodies, fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse and swine anti-rabbit antibodies, as well as appropriate mouse and rabbit isotype control antibodies to provide negative controls were from Dako (Glostrup, Denmark).

Western blotting
Confluent cells were washed with cold PBS and lysed in SDS sample buffer (62 mM Tris pH 6.8, 2% SDS, 0.1 M dithiothreitol, 10% glycerol and 0.05% bromophenol blue). Equal protein amounts (70 μg) were separated by
with FITC-conjugated swine anti-rabbit secondary antibody for 1 h at room temperature and mounted on slides using a fluorescence mounting medium (Dako). The cells were examined with an Olympus BX61 microscope (Olympus Optical Co., Ltd., Tokyo, Japan) and images were obtained using an Olympus DP70 digital camera and DP70-BSW software (version 01.02.). Negative controls were attained by substituting the primary antibody with an appropriate isotype control antibody.

**RNA isolation and RT-PCR**

Total RNA was isolated from cultured BEAS-2B cells using the guanidinium-thiocyanate-phenol-chloroform extraction method [26]. Total RNA concentration was determined on Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Inc., Wilmington, DE, USA) and purity was checked by the A\textsubscript{260}/A\textsubscript{280} ratio (ratios between 1.9 and 2.1 were considered acceptable), in addition, an agarose gel was run to assess the quality. cDNA was synthesized from 5 μg RNA with RevertAid™ H Minus Moloney murine leukemia virus reverse transcriptase (Fermentas, Vilnius, Lithuania) using oligo(dT)\textsubscript{18} priming according to manufacturer’s instructions. The resulting cDNA samples were amplified by polymerase chain reaction (PCR) using a DNA thermal cycler (MJ Research, Watertown, MA, USA) and the following specific oligonucleotide primer pairs: for Tn, forward 5’-CAGCTCCACACITCCAGCTAC-3′ and reverse 5’-CTTTCGGCTGGGCTCAGG-3′ giving a PCR product of 448 bp, for Ln β2 chain, forward 5’-GTCGGCAGTTGATGCTTC-3′ and reverse 5’-GCCGCTCATTTCTCATA-3′ giving a PCR product of 315 bp, for CysLT\textsubscript{1}, forward 5’-AGCCCCCACAAGACATCAA-3′ and reverse 5’-AGGAGAGGCTCAAAGCACA-3′, providing a PCR product size of 358 bp, for CysLT\textsubscript{2}, forward 5’-GCACCATCTCCTCGATT-3′ and reverse 5’-CCAGGAAAAAGCACAACACTC-3′, that gives a PCR product of 392 bp, and for β-actin, forward 5’-TCCCTGGAGAAGAGCTACGA-3′ and reverse 5’-ATCTGCTGAAGGTGGACAG-3′ giving a PCR product of 362 bp. After an initial denaturation at 94°C for 3 min, PCR mixtures were amplified by 35 cycles consisting of 94°C for 25 s, 58°C for 30 s for Tn, by 30 cycles consisting of 94°C for 20 s, 57°C for 25 s, 72°C for 30 s for Ln β2 chain and 35 cycles consisting of 94°C for 10 s, 60°C for 20 s and 72°C for 30 s for the CysLT receptors, with a final extension at 72°C for 5 min. Amplified PCR products were separated by 2% agarose gel electrophoresis, visualized by ethidium bromide and photographed under ultraviolet transillumination together with the 100 bp DNA ladder marker (Fermentas). Omitting either the cDNA from the PCR reaction or reverse transcriptase from the cDNA synthesis reaction provided negative controls.

**Flow cytometry**

For flow cytometry studies, the BEAS-2B cells were washed with PBS, fixed in 2% paraformaldehyde in PBS for 15 min at room temperature and permeabilized in PBS containing 0.1% saponin. A total of 3.0 x 10\textsuperscript{5} cells were resuspended in PBS supplemented with 3% BSA and 0.1% saponin for 30 min. All subsequent steps were performed in PBS containing saponin and BSA. The cells were incubated with the primary antibody against Tn, Ln β2 chain, CysLT\textsubscript{1}, or CysLT\textsubscript{2} for 30 min, washed three times and incubated with the appropriate FITC-conjugated secondary antibody for 30 min. After washing, cells were resuspended in PBS and single-color immunofluorescence analysis of 15 000 cells was performed on a FACS Calibur flow cytometer using CELLQuest software (Becton Dickinson, San Jose, CA, USA). Negative controls were provided by substituting the primary antibody with an appropriate isotype control antibody.

**Immunocytochemistry**

Cells grown on coverslips were fixed with 4% paraformaldehyde in PBS for 15 minutes and permeabilized with 0.1% Triton X-100 in PBS for 10 minutes. The fixed cells were blocked with 3% BSA in PBS prior to incubation for 1 h at room temperature with the primary antibodies against Tn, Ln β2 chain, CysLT\textsubscript{1}, or CysLT\textsubscript{2} (1:10, 1:10, 1:50, and 1:50, respectively). The coverslips were washed three times with PBS and probed with appropriate HRP-conjugated secondary antibodies. The brown immunoperoxidase reaction was developed with diaminobenzidine, followed by hematoxylin counterstaining. The coverslips were mounted face down on microscope slides using a Permanent Mounting Media (Dako). The CysLT receptors were alternatively immunofluorescence-stained with FITC-conjugated swine anti-rabbit secondary antibody for 1 h at room temperature and mounted on slides using a fluorescence mounting medium (Dako). The cells were examined with an Olympus BX61 microscope (Olympus Optical Co., Ltd., Tokyo, Japan) and images were obtained using an Olympus DP70 digital camera and DP70-BSW software (version 01.02.). Negative controls were attained by substituting the primary antibody with an appropriate isotype control antibody.

**RNA isolation and RT-PCR**

Total RNA was isolated from cultured BEAS-2B cells using the guanidinium-thiocyanate-phenol-chloroform extraction method [26]. Total RNA concentration was determined on Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Inc., Wilmington, DE, USA) and purity was checked by the A\textsubscript{260}/A\textsubscript{280} ratio (ratios between 1.9 and 2.1 were considered acceptable), in addition, an agarose gel was run to assess the quality. cDNA was synthesized from 5 μg RNA with RevertAid™ H Minus Moloney murine leukemia virus reverse transcriptase (Fermentas, Vilnius, Lithuania) using oligo(dT)\textsubscript{18} priming according to manufacturer’s instructions. The resulting cDNA samples were amplified by polymerase chain reaction (PCR) using a DNA thermal cycler (MJ Research, Watertown, MA, USA) and the following specific oligonucleotide primer pairs: for Tn, forward 5’-CAGCTCCACACITCCAGCTAC-3′ and reverse 5’-CTTTCGGCTGGGCTTCAGG-3′ giving a PCR product of 448 bp, for Ln β2 chain, forward 5’-GTCGGCAGTTGATGCTTC-3′ and reverse 5’-GCCGCTCATTTCTCATA-3′ giving a PCR product of 315 bp, for CysLT\textsubscript{1}, forward 5’-AGCCCCCACAAGACATCAA-3′ and reverse 5’-AGGAGAGGCTCAAAGCACA-3′, providing a PCR product size of 358 bp, for CysLT\textsubscript{2}, forward 5’-GCACCATCTCCTCGATT-3′ and reverse 5’-CCAGGAAAAAGCACAACACTC-3′, that gives a PCR product of 392 bp, and for β-actin, forward 5’-TCCCTGGAGAAGAGCTACGA-3′ and reverse 5’-ATCTGCTGAAGGTGGACAG-3′ giving a PCR product of 362 bp. After an initial denaturation at 94°C for 3 min, PCR mixtures were amplified by 35 cycles consisting of 94°C for 25 s, 58°C for 30 s for Tn, by 30 cycles consisting of 94°C for 20 s, 57°C for 25 s, 72°C for 30 s for Ln β2 chain and 35 cycles consisting of 94°C for 10 s, 60°C for 20 s and 72°C for 30 s for the CysLT receptors, with a final extension at 72°C for 5 min. Amplified PCR products were separated by 2% agarose gel electrophoresis, visualized by ethidium bromide and photographed under ultraviolet transillumination together with the 100 bp DNA ladder marker (Fermentas). Omitting either the cDNA from the PCR reaction or reverse transcriptase from the cDNA synthesis reaction provided negative controls.
Data analysis

The densitometric analysis of the Western blot and RT-PCR results was performed with use of the Image Pro Plus software (version 4.0, Media Cybernetics Inc., Silver Spring, MD, USA) and the results are expressed as means ± SEM. For statistical analyses, the SPSS statistical package (version 12.0) (Chicago, IL, USA) was applied. Significance was determined by Kruskal-Wallis test with subsequent post hoc analysis between stimulated and control cells using Dunn's multiple comparison test. Two-tailed Mann-Whitney rank sum test was applied for comparison between data of two groups.

Results

Expression of tenascin

Immunoblot analysis of the non-stimulated control cells demonstrated two bands of Tn-immunoreactivity representing polypeptides of Mr 280,000 and Mr 230,000 (Figures 1A, B, and 2B). Exposure of the cells to both LTD₄ and LTE₄ for 48 h augmented the expression of the Tn polypeptide doublet, as well as Tn mRNA in a concentration-dependent manner (Figures 1A, B, and 2A). No significant time-dependence was seen, as analysis of the cells stimulated for 24 and 72 h gave similar results (data not shown). TGF-β₁ also produced a significant increase in Tn at both protein (Figure 2B) and mRNA level (Figure 2C). No Tn was detectable in the culture media, regardless of the treatment setting.

Immunocytochemically, Tn-specific reactivity localized intracellularly in the BEAS-2B cells (Figure 1C) and, like that detected with immunoblot, it increased in response to both LTD₄ and LTE₄. Results from experiments combining 1 ng/ml TGF-beta and 10 nM LTD₄ revealed an addi-

![Figure 1](http://respiratory-research.com/content/9/1/44)

**Figure 1**

**Effect of LTD₄ and LTE₄ on the expression of tenascin (Tn) protein in BEAS-2B human bronchial epithelial cells.** A concentration-dependent increase in expression of Tn was detected by Western blot analysis in cell lysates after exposure of the cells to LTD₄ (A) and to LTE₄ (B) for 48 h. The data were quantified by densitometry and are expressed as fold increases above non-stimulated cells (mean ± SEM) (n = 12). C: Immunoperoxidase immunocytochemistry for Tn showing the basal expression of Tn and an increase by treatment with LTD₄ and with LTE₄. Images are reproduced from a single experiment, but are representative findings of multiple staining experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. non-stimulated cells.
tive effect of both mediators on Tn expression. In particular, the increase in Tn expression represented approximately the sum of the effects achieved by both mediators alone, assessed by both flow cytometry (Figure 2D) and RT-PCR analysis (Figure 2E). Presence of 5 mM L-cysteine in the culture media did not affect the performance of LTD₄ in relevant experimental series (Figures 2D and 2E).

Expression of laminin β2 chain
Immunoblot analysis revealed an insignificant increase in the expression of Ln β2 chain by the BEAS-2B cells from

---

Figure 2
Effect of LTD₄, LTE₄, and TGF-β₁ on the expression of tenascin (Tn) in BEAS-2B human bronchial epithelial cells. RT-PCR analysis detected increased expression of Tn mRNA in response to stimulation with LTD₄ and LTE₄ (A), TGF-β₁ (C), and LTD₄ combined with TGF-β₁ (E) for 48 h. B: Increased expression of Tn was detected by Western blot analysis in cell lysates after stimulation with TGF-β₁ (B) for 48 h. The data were quantified by densitometry and are expressed as fold increases above non-stimulated cells (mean ± SEM) (n = 12). D: Augmented expression of Tn protein was detected by flow cytometry in response to LTD₄ combined with TGF-β₁, compared with the effect of LTD₄ alone. Difference from isotype control mean fluorescence intensity (MFI) is presented (mean ± SEM). Presence of 5 mM L-cysteine in the culture media did not affect the expression levels of Tn (D, E). *p < 0.05, ***p < 0.001, and ****p < 0.0001 vs. non-stimulated cells. NS – non-significant.
the basal level after stimulation with LTD4 and LTE4 for 48 h (data not shown). Immunocytochemistry showed a faint intracellular staining following stimulation with both CysLTs (Figure 3C). However, unlike that with Tn, Western blot analysis of the culture media for Ln β2 chain displayed already a detectable baseline level (Figures 3A and 3B). Media from cultures treated with 10 and 100 nM LTD4 (Figure 3A) but not with LTE4 (Figure 3B) showed a significant increase in Ln β2 chain, but no time-dependence was observed (data not shown). The expression of Ln β2 chain mRNA was significantly up-regulated in BEAS-2B cells by only 100 nM LTD4 (Figure 3D). TGF-β1 did not affect the expression of Ln β2 chain at either protein (data not shown) or mRNA (Figure 3E) level.

Expression of CysLT1 and CysLT2 mRNA and protein
For CysLT1, immunoreactive protein bands with molecular weights of approximately 66, 76, 88, 106, and 111 kDa appeared on Western blots, whereas CysLT2 appeared as 55-, 62-, 117-, 122-, 131-, and a major 148-kDa band (Figure 4A). All these bands were blocked with the respective blocking peptides. At lower protein load (35 μg), only a 148-kDa band for CysLT2 was visible. Immunocytochemistry also confirmed a positive reactivity for both CysLT1 and CysLT2 on BEAS-2B cells that consisted mainly of a bright cytoplasmic staining in all visualized cells. The staining pattern was similar for both receptors, however, immunoreactivity for the CysLT2 was stronger (Figure 4C). Flow cytometric analysis confirmed the presence of both CysLT1 and CysLT2 on BEAS-2B bronchial epithelial cells, as well as corroborated the more vigorous fluorescence for CysLT2 compared to that for CysLT1 (Figure 4D).

RT-PCR analysis revealed the amplified fragments for CysLT1 and CysLT2 that corresponded to the respective expected sizes of the transcripts (Figure 4B). The signal obtained for CysLT2, normalized to β-actin expression, was somewhat higher than that for the CysLT1.

Effect of antileukotrienes on CysLT-induced up-regulation of ECM proteins
Both CysLT receptor antagonists montelukast and BAY u9773 abolished the significant CysLT-induced increase in Tn production at both protein (Figure 5A) and mRNA level (Figure 5B). This inhibition was complete as the levels of Tn expression after receptor blockade did not differ from that in non-stimulated cells. Similarly, the significant up-regulation of expression of Ln β2 chain mRNA by 100 nM LTD4 was fully prevented by both montelukast and BAY u9773 (Figure 6). There was no statistical difference between the inhibitory effects of the CysLT1-specific antagonist montelukast and the dual antagonist BAY u9773 in any setting. In experiments, where LTD4 was combined with 1 ng/ml TGF-β, both montelukast and BAY u9773 reduced the expression of Tn protein and mRNA down to the level not statistically differing from that what was seen after stimulation with TGF-β alone (Figures 5A and 5B). Neither of the antileukotrienes alone significantly affected the baseline Tn and Ln β2 chain expression. Neither montelukast nor BAY u9773 significantly affected the TGF-β-induced Tn-expression (Figures 5A and 5B).

Discussion
In this study, we showed for the first time that CysLTs are able to significantly augment the expression of Tn by human bronchial epithelial cells. However, only LTD4 is potent enough to enhance the expression of Ln β2 chain. We also demonstrated that the CysLT-induced increase in Tn and Ln β2 chain is mediated solely by the CysLT1 receptor, as montelukast, a specific CysLT1 inhibitor, completely abolished this increase and dual inhibition of both CysLT receptors did not provide any significant additional effect.

It is remarkable that the CysLTs can produce increased expression of Tn and Ln β2 chain even alone suggesting that they act as independent remodeling-inducing mediators at least on human bronchial epithelial cells. This is apart from that shown in a former study on human lung fibroblasts in which LTD4 only augmented TGF-β-induced collagen production, but had no effect alone [12]. One could argue, however, for that the increased collagen leading to fibrosis on the one hand and Tn along with Ln β2 chain on the other may convey somewhat different significance with regard to tissue remodeling. Indeed, in contrast to collagens, Tn is an ECM protein, which shows rapid tissue turnover represented by prompt increase followed by a decrease either after discontinuation of the adverse situation [10] or as a result of treatment [7]. However, increased Tn has been suggested to have dual significance within the airways. Beyond the role of acutely up-regulated Tn in the inflammatory response and cell trafficking, the deposition of Tn into the airway mucosa provides an addition to the increased accumulation of the ECM components, such as collagens, leading to increased airway narrowing and reduction in airway wall compliance [10]. The accumulation of collagens and Tn share even more common aspects. Tn is a matricellular protein that facilitates both morphogenesis of epithelial organs and re-epithelization after injury, but is also responsible for correct rebuilding of the ECM, including proper deposition of collagen [27]. This pertains with minor reservations also to the Ln β2 chain, which is transiently expressed at the epithelial-mesenchymal border and mediates morphogenetic events and organization of the basement membrane (BM) up to the canalicular stage of lung development [28]. In addition, increased expression of both Tn [7] and Ln β2 chain [5] have been shown in the subepithelial BM in patients with asthma in a manner par
Effect of LTD₄, LTE₄ and TGF-β₁ on the expression of laminin (Ln) β₂ chain in BEAS-2B human bronchial epithelial cells. Western blot analysis revealed increased expression of Ln β₂ chain in the cell culture medium in response to stimulation with LTD₄ (A), but not with LTE₄ (B) for 48 h. RT-PCR analysis detected increased expression of Ln β₂ chain mRNA in response to 100 nM LTD₄ (D), but no effect with either LTE₄ (D) or TGF-β₁ (E). The increase in response to LTD₄ was concentration-dependent. The data were quantified by densitometry and are expressed as fold increases above non-stimulated cells (mean ± SEM) (n = 12). *p < 0.05 and ***p < 0.001 vs. non-stimulated cells. C: Immunoperoxidase immunocytochemistry for Ln β₂ chain showing no definite expression of Ln β₂ chain by non-stimulated control cells with a slight increase after treatment with both LTD₄ and LTE₄. Images are reproduced from a single experiment, but are representative findings of multiple staining experiments.
Figure 4
Analysis of cysteinyl leukotriene receptors CysLT\(_1\) and CysLT\(_2\) in BEAS-2B human bronchial epithelial cells. A: Western blot analysis of CysLT\(_1\) and CysLT\(_2\) protein in the presence or absence of specific blocking peptide (BP) with increasing amount of protein loaded. B: RT-PCR analysis of CysLT\(_1\) and CysLT\(_2\) mRNA. The graph represents densitometric results of CysLT\(_1\) and CysLT\(_2\), normalized to β-actin (mean ± SEM) (n = 9). *p < 0.05. C: Indirect FITC-immunofluorescence staining showing localization of cysteinyl leukotriene receptors in non-stimulated cells. D: Representative flow cytometric analysis of CysLT\(_1\) and CysLT\(_2\) on BEAS-2B cells. The open histograms correspond to cells labeled with isotype control antibody and the shaded ones represent cells labeled with the respective anti-CysLT antibodies.
Inhibition by antileukotrienes of tenascin (Tn) expression in cysteinyl leukotriene-stimulated BEAS-2B human bronchial epithelial cells.

Figure 5
Inhibition by antileukotrienes of tenascin (Tn) expression in cysteinyl leukotriene-stimulated BEAS-2B human bronchial epithelial cells. A: Flow cytometric analysis showed full inhibition by both montelukast (MLK) and BAY u9773 of LTD4- or LTE4-induced increase in Tn protein expression to the levels not differing from that in non-stimulated cells. Difference from isotype control mean fluorescence intensity (MFI) is presented. B: RT-PCR analysis of Tn mRNA showing inhibition of the cysteinyl leukotriene-induced up-regulation by both MLK and BAY u9773. Partial inhibition of Tn expression induced by combined LTD4 and TGF-β1 down to the level not differing from that what was seen after stimulation with TGF-β1 alone was shown at both protein (A) and mRNA (B) level. There was no statistical difference between the inhibitory effects of MLK and BAY u9773 in any setting. Data are expressed as mean ± SEM (n = 12) *p < 0.05, **p < 0.01, and ***p < 0.001. NS – non-significant.
Figure 6
Inhibition by antileukotrienes of laminin (Ln) β2 chain expression in cysteinyl leukotriene-stimulated BEAS-2B human bronchial epithelial cells. RT-PCR analysis of Ln β2 chain mRNA showing significant inhibition of the 100 nM LTD₄-induced up-regulation by both montelukast (MLK) and BAY u9773. There was no statistical difference between the inhibitory effects of MLK and BAY u9773. Data are expressed as mean ± SEM (n = 12) *p < 0.05, **p < 0.01, and ***p < 0.001.

Allowing the severity and duration of the disease. Not only this refers to the involvement of these proteins in the remodeling of the ECM, but suggests also a reverse quantitative expression pattern, compared to that observed during the human fetal airway morphogenesis. In this light, the increased synthesis of Tn and Ln β2 chain by bronchial epithelial cells in response to CysLTs in the present study may be reminiscent of an inflammatory response in which CysLT-rich milieu is a characteristic feature, like this is the case in asthma [29]. It has been suggested that inflammatory mediator-induced submucosal remodeling is initiated through the bronchial epithelium [30]. According to this widely accepted model, the stimulated or injured epithelial cells drive the mesenchymal cells within the epithelial-mesenchymal trophic unit in a way similar to the processes during the fetal development [3]. Our present findings supplement this knowledge with the ability of the bronchial epithelial cells to contribute to the airway remodeling even independently on the communication with mesenchymal cells.

To strengthen the evidence that CysLTs act directly on the human bronchial epithelial cells that results in increased Tn and Ln β2 chain synthesis, we next focused on the expression of the two CysLT receptors on these cells. Of the overall human respiratory epithelium, the presence of CysLT₁ and CysLT₂ have been formerly described immunohistochemically on nasal mucosal epithelium in both healthy individuals and patients with chronic rhinosinusitis [31]. Both CysLT receptors have been described also in the epithelium of palatine tonsils of pediatric patients with sleep apnea and recurrent throat infections [32]. Recently, with use of immunohistochemistry and in situ hybridization, a weak and moderate expression of CysLT₁ has been described in bronchial epithelial cells of controls and asthmatics, respectively [33]. Interestingly, only some but not all bronchial epithelial cells appeared to show expression of the CysLT₁ protein in that particular study and unfortunately, expression of CysLT₂ was not addressed. Thus, the expression of both CysLT receptors on BEAS-2B human bronchial epithelial cells at both mRNA and protein level in the present study is partly in line with and partly supplement the data obtained by previous investigators. The evidence we have obtained that the CysLT₂ is more abundant on human bronchial epithelial cells than the CysLT₁, is supported by the results of a immunohistochemical study of Corrigan and co-authors on nasal epithelial cells [31]. RT-PCR analyses in our present study did support our immunofluorescence and flow cytometry findings strengthening the possibility that the stronger immunoreactivity for CysLT₁ reflects the true higher expression of CysLT₂ compared to that of CysCT₁ rather than results from different antibody performances. Our Western blot analysis of the CysLT₁ displayed several protein bands, which obviously correspond to the oligomeric forms (Figure 4A). This is in agreement with previous reports, which along with the monomeric form have demonstrated larger amounts of dimmerized and oligomerized CysLT₁ in the presence of denaturing gel detergent [34]. When probing for CysLT₂, also several specific immunoreactive bands were detected with a major band at approximately 148 kDa, corresponding most likely to the oligomers of the receptor. Although the evidence that the CysLT receptor immunoreactivity was completely blocked by the blocking peptides supports the specificity of the detected bands, the molecular weights do not precisely correspond to monomers and homo-oligomers of the CysLT receptors. This could be explained by post-translational modifications, but rather by the possibility of composing heterodimers and hetero-oligomers, which is a characteristic feature of G-protein-coupled receptors [35].

The CysLT-induced increase in Tn and Ln β2 chain production by bronchial epithelial cells was completely abolished by both CysLT₁-specific antagonist montelukast and a dual antagonist for both CysLT₁ and CysLT₂ receptors, BAY u9773. Furthermore, increased Tn expression as a result of combined stimulation with LTD₄ and 1 ng/ml TGF-β was reduced by both montelukast and BAY u9773 down to the levels not statistically differing from that what was seen after stimulation with TGF-β alone. This may refer to the possibility that CysLTs may affect Tn
expression independently of TGF-β. Since montelukast appeared to be sufficient to block the effect of the CysLTs and there was no difference between the two antileukotrienes for their inhibition activities, the results allow us to suggest that the CysLT-induced increase in Tn and Ln β2 chain in bronchial epithelial cells is mediated through the CysLT₁ receptor.

**Conclusion**

Our present results demonstrate for the first time that the CysLTs LTD₄ and LTE₄ augment production of Tn, whereas LTD₄ enhances also synthesis of Ln β2 chain by human bronchial epithelial cells and this effect is mediated via the CysLT₁ receptor. The results not only point to the possibility that, when exposed to CysLTs, the epithelial cells can participate in the development of airway remodeling independently on communication within the epithelial-mesenchymal trophic unit, but also implies that treatment with CysLT₁ receptor antagonists can be effective to suppress this important mechanism of airway remodeling in asthma.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

SA conceived and designed the study, coordinated all stages of the laboratory-based experiments and analyzed the flow cytometry, Western blot, and RT-PCR results. She also contributed significantly in preparation of the manuscript, MK and ER handled the cell work, as well as analysis of the results, as well as were involved in drafting the manuscript, AA elaborated the conception and participated in the design of the study, accomplished the data analysis, supervised the interpretation of the data, and critically evaluated and supplemented the manuscript.

**Acknowledgements**

The present work was supported by research grants No. 5011, 6566, and 7154 from the Estonian Science Foundation and Core Grants from the Estonian Ministry of Education and Science (No. 0182582s03 and 0182560s03).

**References**

1. Hogg JC, Chu F, Uotskoparch S, Woods R, Elliott WM, Buzauro L, Cherniack RM, Rogers RM, Scoura FC, Coxson HO, Pare PD: The nature of small-airway obstruction in chronic obstructive pulmonary disease. **N Engl J Med** 2004, 350(26):2645-2653.

2. Jeffery PK: Remodeling in asthma and chronic obstructive lung disease. **Am J Respir Crit Care Med** 2001, 164(10 Pt 2):S28-38.

3. Davies DE, Wickj J, Powell RM, Puddicombe SM, Holgate ST: Airway remodeling in asthma: new insights. **J Allergy Clin Immunol** 2003, 111(2):215-25; quiz 226.

4. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G: A 15-year follow-up study of ventilatory function in adults with asthma. **N Engl J Med** 1998, 339(17):194-1200.

5. Altraja A, Laitinen A, Virtanen I, Karlsson SE, Hakansson L, Venge P, Sillastu H, Laitinen LA: Expression of laminins in the airways in various types of asthmatic patients: a morphometric study. **Am J Respir Cell Mol Biol** 1996, 15(4):482-488.

6. Chakraborty S, Shannon J, Molet S, Fukakusa M, Elias J, Laviolle M, Boulet LP, Hamid Q: Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. **J Allergy Clin Immunol** 2003, 111(6):1293-1298.

7. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA: Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. **Am J Respir Crit Care Med** 1997, 156(3 Pt 1):951-958.

8. Linnala A, Kinnula V, Laitinen LA, Lehto VP, Virtanen I: Transforming growth factor-beta regulates the expression of fibronectin and tenasin in BEAS 2B human bronchial epithelial cells. **Am J Respir Cell Mol Biol** 1995, 13(5):578-585.

9. Harkonen E, Virtanen I, Linnala A, Linden M, Kinnula VL: Modulation of fibronectin and tenasin production in human bronchial epithelial cells and inflammatory cytokines in vitro. **Am J Respir Cell Mol Biol** 1995, 13(1):109-115.

10. Karikawasam HH, Aizen M, Barkans J, Robinson DS, Kay AB: Remodeling and airway hyperresponsiveness but not cellular inflammation persist after allergen challenge in asthma. **Am J Respir Crit Care Med** 2007, 175(11):1312-1326.

11. Montuosi P, Sala A, Dahlen SE, Folco G: Cysteinyl-leukotriene type 1 receptor internalization and signaling. **J Biol Chem** 2005, 280(10):8722-8732.

12. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia G, Bonsignore G: Airway remodeling-associated mediators in allergic airway disease. **Drug Discov Today** 2007, 12(9-10):404-412.

13. Espinosa K, Bosse Y, Stankova J, Rola-Pleszczynski M: CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD₄. **J Allergy Clin Immunol** 2003, 111(5):1032-1040.

14. Wells MM, Chakraborty S, Vethanayagam D, Boulet LP, Laviolle M, Gauldie J, O’Byrne PM: Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. **Ann Allergy Asthma Immunol** 2006, 130(3):741-743.

15. Montuschi P, Sala A, Dahlen SE, Folco G: Pharmacological modulation of the leukotriene pathway in allergic airway disease. **Drug Discov Today** 2007, 12(9-10):404-412.

16. Capra V: Molecular and functional aspects of human cysteinyl leukotriene receptors. **Pharmacol Res** 2004, 50(1):1-11.

17. Kanaoka Y, Boyce JA: Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. **J Immunol** 2004, 173(3):1503-1510.

18. Nak S, Billington CK, Pascoal RM, Devendre DA, Stefano FP, Kohout TA, Eckman DM, Benovic JL, Penn RB: Regulation of cysteinyl leukotriene type I receptor internalization and signaling. **J Biol Chem** 2005, 280(10):8722-8732.

19. Nielsen CK, Campbell JH, Ohd MJ, Morgen M, Rieseck BK, Landberg G, Spolander A: A novel localization of the G-protein coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. **Cancer Res** 2005, 65(3):732-742.

20. Busse W, Kraft M: Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. **Chest** 2005, 127(4):1312-1326.

21. Capra V, Ambrosio M, Riccioni G, Rovati GE: Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. **Curr Med Chem** 2006, 13(26):3213-3226.

22. Henderson WR Jr., Chiang GK, Tien YT, Chi EY: Reversal of allergic-induced airway remodeling by LTD₄ by CysLT₁ receptor blockade. **Am J Respir Crit Care Med** 2006, 173(7):718-728.

23. Holgate ST, Holloway J, Wilson S, Bucchieri F, Puddicombe SM, Holgate ST: Cysteinyl-leukotriene type 1 receptor internalization and signaling. **J Biol Chem** 2005, 280(10):8722-8732.

24. Nielsen CK, Campbell JH, Ohd MJ, Morgen M, Rieseck BK, Landberg G, Spolander A: A novel localization of the G-protein coupled CysLT1 receptor in the nucleus of colorectal adenocarcinoma cells. **Cancer Res** 2005, 65(3):732-742.

25. Busse W, Kraft M: Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. **Chest** 2005, 127(4):1312-1326.

26. Capra V, Ambrosio M, Riccioni G, Rovati GE: Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. **Curr Med Chem** 2006, 13(26):3213-3226.

27. Henderson WR Jr., Chiang GK, Tien YT, Chi EY: Reversal of allergic-induced airway remodeling by LTD₄ by CysLT₁ receptor blockade. **Am J Respir Crit Care Med** 2006, 173(7):718-728.
27. Midwood KS, Williams LV, Schwarzbauer JE: Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 2004, 36(6):1031-1037.

28. Virtanen I, Laitinen A, Tani T, Paakko P, Laitinen LA, Burgeson RE, Lehto VP: Differential expression of laminins and their integrin receptors in developing and adult human lung. Am J Respir Cell Mol Biol 1996, 15(2):184-196.

29. Hanazawa T, Kharitonov SA, Barnes PJ: Increased nitrotyrosine in exhaled breath condensate of patients with asthma. Am J Respir Crit Care Med 2000, 162(4 Pt 1):1273-1276.

30. Richter A, Puddicombe SM, Lordan JL, Bucchiere F, Wilson SJ, Djukanovic R, Dent G, Holgate ST, Davies DE: The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001, 25(3):385-391.

31. Corrigan C, Mallett K, Ying S, Roberts D, Parikh A, Scadding G, Lee T: Expression of the cysteinyl leukotriene receptors cysLT(1) and cysLT(2) in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 2005, 115(2):316-322.

32. Goldbart AD, Goldman JL, Li RC, Brittan KR, Tauman R, Gozal D: Differential expression of cysteinyl leukotriene receptors I and 2 in tonsils of children with obstructive sleep apnea syndrome or recurrent infection. Chest 2004, 126(1):13-18.

33. Zhu J, Qiu YS, Figueroa DJ, Bandi V, Galczenski H, Hamada K, Gunupalli KK, Evans JF, Jeffery PK: Localization and upregulation of cysteinyl leukotriene-I receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 2005, 33(6):531-540.

34. Figueroa DJ, Breyer RM, Defoe SK, Kargman S, Daugherty BL, Waldburger K, Liu Q, Clements M, Zeng Z, O'Neill GP, Jones TR, Lynch KR, Austin CP, Evans JF: Expression of the cysteinyl leukotriene I receptor in normal human lung and peripheral blood leukocytes. Am J Respir Crit Care Med 2001, 163(1):226-233.

35. Devi LA: Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 2001, 22(10):532-537.